ScholarIQanswers from OpenAlex
International Breast Cancer Study Group
InstitutionResearch output, impact & collaborations
International Breast Cancer Study Group is a institution indexed in ScholarIQ from OpenAlex.
What is known about International Breast Cancer Study Group?
ScholarIQrecord summary
International Breast Cancer Study Group is a research organisation in Bern, CH. OpenAlex records 884 works and 257,054 citations for it. 223 researchers list it as their most recent affiliation.
How many works does International Breast Cancer Study Group have?
ScholarIQindexed works
International Breast Cancer Study Group has 884 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does International Breast Cancer Study Group have?
ScholarIQcitation count
International Breast Cancer Study Group has 257,054 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at International Breast Cancer Study Group?
ScholarIQresearcher count
International Breast Cancer Study Group has 223 researchers in the ScholarIQ index.
What is the average h-index at International Breast Cancer Study Group?
ScholarIQavg h-index
International Breast Cancer Study Group has an average h-index of 85 in OpenAlex.
What is the ROR of International Breast Cancer Study Group?
ScholarIQror
The ROR for International Breast Cancer Study Group is on the source record.
What is the OpenAlex record for International Breast Cancer Study Group?
ScholarIQopenalex
The OpenAlex for International Breast Cancer Study Group is on the source record.
Who are the most-cited researchers behind International Breast Cancer Study Group?
ScholarIQtop researchers by citations
What are the most-cited papers on International Breast Cancer Study Group?
ScholarIQmost cited works
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
Sherene Loi, Anita Giobbie‐Hurder, Andrea Gombos, Thomas Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, Hervé Bonnefoi, Guy Jérusalem, Rupert Bartsch, Manuela Rabaglio, Roswitha Kammler, Rudolf Maibach, Mark J. Smyth, Angelo Di Leo, Marco Colleoni, Giuseppe Viale, Meredith M. Regan, Fabrice André, Debora Fumagalli, Richard D. Gelber, Theodora Goulioti, Anita Hiltbrunner, Rita L. Hui, Heidi Roschitzki, Barbara Ruepp, Frances M. Boyle, Rolf A. Stahel, Stefan Aebi, Alan S. Coates, Aron Goldhirsch, Per Karlsson, Ingrid Kössler, Stamatina Fournarakou, Adriana Gasca, Rita Pfister, Sabrina Ribeli-Hofmann, Magdelena Weber, Daniela Celotto, Carmen Comune, M. Frapolli, Magdalena Sánchez-Hohl, Hui Huang, Caitlin Mahoney, Karen N. Price, Karolyn Scott, Holly Shaw, Susan M. Fischer, Mónica Greco, Colleen King, Stefania Andrighetto, Martine Piccart, Heather E. Findlay, Michelle Jenkins, Vassiliki Karantza, Jaime Mejia, Patrick Schneier
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
K.M. Kerr, L. Bubendorf, Martin J. Edelman, Andrea Ascoli Marchetti, Tony Mok, Silvia Novello, Kenneth J. O’Byrne, Rolf A. Stahel, Solange Peters, Enriqueta Felip, Rolf A. Stahel, Enriqueta Felip, Solange Peters, Keith M. Kerr, Benjamin Besse, Johan Vansteenkiste, Wilfried Eberhardt, Martin J. Edelman, Tony Mok, Kenneth J. O’Byrne, Silvia Novello, Lukas Bubendorf, Antonio Marchetti, Paul Baas, Martin Reck, Konstantinos Syrigos, Luis Paz‐Ares, Egbert F. Smit, Peter Meldgaard, Alex A. Adjei, M. Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre‐Finn, Gaetano Rocco, Giulia Veronesi, Jean-Yves Douillard, Eric Lim, Christophe Dooms, W. Weder, Dirk De Ruysscher, C. Le Péchoux, Paul De Leyn, Virginie Westeel
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers
Solange Peters, Rolf A. Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M. Kowalski, Christina S. Baik, Dolores Isla, Javier de Castro, Pilar Garrido, Achim Rittmeyer, Marcello Tiseo, Christoph Meyenberg, Sanne de Haas, Lisa H. Lam, Michael W. Lu, Thomas E. Stinchcombe
How much of the research on International Breast Cancer Study Group is open access?
ScholarIQopen access share
67%OPEN ACCESS